KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase

European Journal of Pharmacology

Volumn 632, Issue 1-3, 2010, Pages 93-102

  Montalban, Antonio Garrido ^a   Boman, Erik ^a   Chang, Chau Dung ^a   Ceide, Susana Conde ^a   Dahl, Russell ^a   Dalesandro, David ^a   Delaet, Nancy G J ^a   Erb, Eric ^a   Ernst, Justin ^a   Gibbs, Andrew ^a   Kahl, Jeffrey ^a   Kessler, Linda ^a   Lundström, Jan ^a   Miller, Stephen ^a   Nakanishi, Hiroshi ^a   Roberts, Edward ^a   Saiah, Eddine ^a   Sullivan, Robert ^a   Wang, Zhijun ^a   Larson, Christopher J ^a  

^a Kemia Inc   (United States)

Author keywords

Arthritis; Inhibitor; Kinase; p38; TNF (Tumor necrosis factor)

Indexed keywords

5 TERT BUTYL N CYCLOPROPYL 2 METHOXY 3 [2 [4 (2 MORPHOLIN 4 YL ETHOXY)NAPTHALEN 1 YL] 2 OXO ACETYLAMINO]BENZAMIDE; CARRAGEENAN; DORAMAPIMOD; INDOMETACIN; KR 003048; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTHRITIS; ARTICLE; BINDING AFFINITY; BONE EROSION; CHONDROPATHY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYNOVITIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ARTHRITIS, RHEUMATOID; BENZAMIDES; CELLS, CULTURED; ENZYME INHIBITORS; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 14; MODELS, CHEMICAL; MODELS, IMMUNOLOGICAL; MODELS, MOLECULAR; MONOCYTES; MORPHOLINES; OSTEOPOROSIS; PHOSPHORYLATION; RATS; RATS, INBRED LEW; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77349118681     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.01.011     Document Type: Article

References (42)

1. Alonzi T., Fattori E., Cappelletti M., Ciliberto G., and Poli V. Impaired Stat3 activation following localized inflammatory stimulus in IL-6-deficient mice. Cytokine 10 (1998) 13-18
2. Badger A.M., Bradbeer J.N., Votta B., Lee J.C., Adams J.L., and Griswold D.E. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. 279 (1996) 1453-1461
3. Badger A.M., Cook M.N., Lark M.W., Newman-Tarr T.M., Swift B.A., Nelson A.H., Barone F.C., and Kumar S. SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J. Immunol. 161 (1998) 467-473
4. Bingham III C.O. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J. Rheumatol. Suppl. 65 (2002) 3-9
5. Campbell I.K., O'Donnell K., Lawlor K.E., and Wicks I.P. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J. Clin. Invest. 107 (2001) 1519-1527
6. de Winter R.J., Tijssen J.G.P., Windhaussen F., Slagboom T., Krasznai K., Michels H.R., Dunselman P.H.J.M., vant Hof A.N.G., Bosschaert M., Suttorp M.J., Merica E., Godfrey C.J., Ogenstad S., Williams L., Martin-Munley S., Kauffman R., and Mohanlal R. A major determinant of C-reactive protein production in patients with acute coronary syndrome undergoing PCI: the p38 mitogen activated protein kinase pathway (2005), American Heart Association Scientific Sessions, Dallas, Texas
7. Diller D.J., Lin T.H., and Metzger A. The discovery of novel chemotypes of p38 kinase inhibitors. Curr. Top. Med. Chem. 5 (2005) 953-965
8. Dominguez C., Tamayo N., and Zhang D. p38 inhibitors: beyond pryidinylimidazoles. Expert Opin. Ther. Pat. 15 (2005) 801-816
9. Faour W.H., He Y., He Q.W., de L.M., Quintero M., Mancini A., and Di Battista J.A. Prostaglandin E(2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J. Biol. Chem. 276 (2001) 31720-31731
10. Garrido Montalban A., Boman E., Chang C.-D., Conde Ceide S., Dahl R., Dalesandro D., Delaet N.G.J., Erb E., Ernst J.T., Gibbs A., Kahl J., Kessler L., Lundström J., Miller S., Nakanishi H., Roberts E., Saiah E., Sullivan R., Wang Z., and Larson C.J. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors. Bioorg. Med. Chem. Lett. 18 (2008) 1772-1777
11. Han J., Lee J.D., Tobias P.S., and Ulevitch R.J. Endotoxin induces rapid protein tyrosine phosphorylation in 70Z/3 cells expressing CD14. J. Biol. Chem. 268 (1993) 25009-25014
12. Han J., Lee J.D., Bibbs L., and Ulevitch R.J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265 (1994) 808-811
13. Hannigan M.O., Zhan L., Ai Y., Kotlyarov A., Gaestel M., and Huang C.K. Abnormal migration phenotype of mitogen-activated protein kinase-activated protein kinase 2-/- neutrophils in Zigmond chambers containing formyl-methionyl-leucyl-phenylalanine gradients. J. Immunol. 167 (2001) 3953-3961
14. Herlaar E., and Brown Z. p38 MAPK signalling cascades in inflammatory disease. Mol. Med. Today 5 (1999) 439-447
15. Hynes Jr. J., and Leftheri K. Small molecule p38 inhibitors: novel structural features and advances from 2002-2005. Curr. Top. Med. Chem. 5 (2005) 967-985
16. Kontoyiannis D., Boulougouris G., Manoloukos M., Armaka M., Apostolaki M., Pizarro T., Kotlyarov A., Forster I., Flavell R., Gaestel M., Tsichlis P., Cominelli F., and Kollias G. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J. Exp. Med. 196 (2002) 1563-1574
17. Kotlyarov A., Yannoni Y., Fritz S., Laass K., Telliez J.B., Pitman D., Lin L.L., and Gaestel M. Distinct cellular functions of MK2. Mol. Cell. Biol. 22 (2002) 4827-4835
18. Kyriakis J.M., and Avruch J. Sounding the alarm: protein kinase cascades activated by stress and inflammation. J. Biol. Chem. 271 (1996) 24313-24316
19. Kyriakis J.M., Banerjee P., Nikolakaki E., Dai T., Rubie E.A., Ahmad M.F., Avruch J., and Woodgett J.R. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369 (1994) 156-160
20. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., McNulty D., Blumenthal M.J., Heys J.R., and Landvatter S.W. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372 (1994) 739-746
21. McGinty A., Foschi M., Chang Y.W., Han J., Dunn M.J., and Sorokin A. Induction of prostaglandin endoperoxide synthase 2 by mitogen-activated protein kinase cascades. Biochem. J. 352 Pt 2 (2000) 419-424
22. Michelotti E.L., Moffett K.K., Nguyen D., Kelly M.J., Shetty R., Chai X., Northrop K., Namboodiri V., Campbell B., Flynn G.A., Fujimoto T., Hollinger F.P., Bukhtiyarova M., Springman E.B., and Karpusas M. Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. Bioorg. Med. Chem. Lett. 15 (2005) 5274-5279
23. Natarajan S.R., and Doherty J.B. P38 MAP kinase inhibitors: evolution of imidazole-based and pyrido-pyrimidin-2-one lead classes. Curr. Top. Med. Chem. 5 (2005) 987-1003
24. Nemeth E., Bole-Feysot C., and Tashima L.S. Suppression subtractive hybridization (SSH) identifies prolactin stimulation of p38 MAP kinase gene expression in Nb2 T lymphoma cells: molecular cloning of rat p38 MAP kinase. J. Mol. Endocrinol. 20 (1998) 151-156
25. Ono K., and Han J. The p38 signal transduction pathway: activation and function. Cell. Signal. 12 (2000) 1-13
26. Pargellis C., and Regan J. Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis. Curr. Opin. Investig. Drugs 4 (2003) 566-571
27. Pargellis C., Tong L., Churchill L., Cirillo P., Gilmore T., Graham A., Grob P., Hickey E., Moss N., Pav S., and Regan J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9 (2002) 268-272
28. Redlich K., Schett G., Steiner G., Hayer S., Wagner E., and Smolen J. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum. 48 (2003) 3308-3319
29. Regan J., Breitfelder S., Cirillo P., Gilmore T., Graham A., Hickey E., Klaus B., Madwed J., Moriak M., Moss N., Pargellis C., Pav S., Proto A., Swinamer A., Tong L., and Torcellini C. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J. Med. Chem. 45 (2002) 2994-3008
30. Regan J., Capolino A., Cirillo P., Gilmore T., Graham A., Hickey E., Kroe R., Madwed J., Moriak M., Nelson R., Pargellis C., Swinamer A., Torcellini C., Tsang M., and Moss N. Structure-activity relationships of the p38r MAP kinase inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]urea (BIRB 796). J. Med. Chem. 46 (2003) 4676-4686
31. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr. Opin. Pharmacol. 4 (2004) 372-377
32. Sasai M., Saeki Y., Ohshima S., Nishioka K., Mima T., Tanaka T., Katada Y., Yoshizaki K., Suemura M., and Kishimoto T. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 42 (1999) 1635-1643
33. Schreiber S., Feagan B., D'Haens G., Colombel J.F., Geboes K., Yurcov M., et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 4 (2006) 325-334
34. Sekut L., Menius Jr. J.A., Brackeen M.F., and Connolly K.M. Evaluation of the significance of elevated levels of systemic and localized tumor necrosis factor in different animal models of inflammation. J. Lab. Clin. Med. 124 (1994) 813-820
35. Shi Y., and Gaestel M. In the cellular garden of forking paths: how p38 MAPKs signal for downstream assistance. Biol. Chem. 383 (2002) 1519-1536
36. Stuart J.M., Cremer M.A., Townes A.S., and Kang A.H. Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J. Exp. Med. 155 (1982) 1-16
37. Tong L., Pav S., White D., Rogers S., Crane K., Cywin C., Brown M., and Pargellis C. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat. Struct. Biol. 4 (1997) 311-316
38. Waetzig G., Seegert D., Rosenstiel P., Nikolaus S., and Schreiber S. p38 mitogen-activated protein kinase is activated and linked to TNF-α signaling in inflammatory bowel disease. J. Immunol. 168 (2002) 5342-5351
39. Wang X., Xu L., Wang H., Young P.R., Gaestel M., and Feuerstein G.Z. Mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 deficiency protects brain from ischemic injury in mice. J. Biol. Chem. 277 (2002) 43968-43972
40. Weisman M., Furst D., Schiff M., Kauffman R., Merica E., and Martin-Munley S. A double-blind, placebo-controlled trial of VX-745, an oral p38 mitogen activated protein kinase (MAPK) inhibitor, in patients with rheumatoid arthritis. Official meeting of the European League Against Rheumatism, Annual European Congress of Rheumatology, Stockholm, Sweden (2002)
41. Williams R.O., Feldmann M., and Maini R.N. Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha. Ann. Rheum. Dis. 59 Suppl 1 (2000) i75-i80
42. Wilson K.P., McCaffrey P.G., Hsiao K., Pazhanisamy S., Galullo V., Bemis G.W., Fitzgibbon M.J., Caron P.R., Murcko M.A., and Su M.S. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 4 (1997) 423-431